US Edition
After Obtaining Approval for Its Weight Loss Pill, Is It Off to the Races for Eli Lilly Stock?
19 Articles
19 Articles
After Obtaining Approval for Its Weight Loss Pill, Is It Off to the Races for Eli Lilly Stock?
Key PointsA weight loss pill would help Eli Lilly reach a broader segment of the population.Its existing GLP-1 drugs have already been generating billions in revenue growth for the business.The stock's high earnings multiple may be deterring some investors today.10 stocks we like better than Eli Lilly › On April 1, Eli Lilly (NYSE: LLY) and its shareholders received the news they were eagerly awaiting: the approval of the company's GLP-1 pill, F…
Telemundo Area de la Bahía 48
The Food and Drug Administration (FDA) is asking Eli Lilly to collect more safety data on his new weight loss pill, Fondayo, including whether it could be linked to liver and heart problems, according to the online approval letter published on Tuesday. Fondayo obtained FDA approval this month under the Commissioner’s National Priority Voucher, a pilot program aimed at accelerating drug review. The pill is the second oral LPG-1 to reach the marke…
Coverage Details
Bias Distribution
- 100% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
